IP Library › Granted Patent US 10,696,747
Granted Patent B2
US 10,696,747 · App. 16/112,008 · Granted Jun 30, 2020

IL2R common gamma chain antibodies

Inventors: Cheng-I Wang (Singapore, SG); Peter Brauer (Singapore, SG); Siok Ping Yeo (Singapore, SG); Hwee Ching Tan (Singapore, SG); John Edward Connolly (Singapore, SG)
Assignee: Agency for Science, Technology and Research
C07K16/2866A61K39/3955A61K47/6849C07K16/1036C07K16/468A61K38/1709A61K2039/505A61K2039/57C07K2317/31C07K2317/33C07K2317/51C07K2317/515C07K2317/524C07K2317/526C07K2317/565C07K2317/60C07K2317/622C07K2317/64C07K2317/75C07K2317/76C07K2317/92C07K2317/94C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,696,747
App. No.
16/112,008
Granted
Jun 30, 2020
Kind
B2
Abstract

Anti-CD122 and/or γc antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.

Claims (30)

1. An isolated antibody or antigen binding fragment which specifically binds to common γ chain (γc), and comprises:

(i) a light chain variable region comprising the following CDRs:

LC-CDR1:

(SEQ ID NO: 68)

RSSQSLLHSNGYNYLD

LC-CDR2:

(SEQ ID NO: 69)

LGSNRDS

LC-CDR3:

(SEQ ID NO: 70)

MQGTHWPWT;

and

(ii) a heavy chain variable region comprising the following CDRs:

HC-CDR1:

(SEQ ID NO: 48)

GYYWS

HC-CDR2:

(SEQ ID NO: 49)

EINHSGSTNYNPSLKS

HC-CDR3:

(SEQ ID NO: 77)

SPGGYSGGYFQH.

2. The isolated antibody or antigen binding fragment according to claim 1 , wherein:

the light chain variable region sequence has at least 70% sequence identity to SEQ ID NO:67, and

the heavy chain variable region sequence has at least 70% sequence identity to SEQ ID NO:76.

3. The isolated antibody or antigen binding fragment according to claim 1 , wherein:

the light chain variable region sequence has at least 85% sequence identity to SEQ ID NO:67, and

the heavy chain variable region sequence has at least 85% sequence identity to SEQ ID NO:76.

4. The isolated antibody or antigen binding fragment according to claim 1 , conjugated to a drug moiety or a detectable moiety.

5. A bispecific antibody comprising the antibody or antigen binding fragment of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2018
From: WANG, CHENG-I; BRAUER, PETER; YEO, SIOK PING; TAN, HWEE CHING; CONNOLLY, JOHN EDWARD
To: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Reel/Frame 046700/0419 →
Priority Claims (1)
SG 10201506227V · Aug 6, 2015 · national
Continuity (2)
Continuation 15750425
Related Publication 20180362655A1 · Dec 20, 2018
Cited By (1)
US 12,234,291